PDF(Pubmed)
Abstract：
The endogenous cannabinoid system (ECS) of the brain plays an important role in the molecular pathogenesis of Parkinson\'s disease (PD). It is involved in the formation of numerous clinical manifestations of the disease by regulating the level of endogenous cannabinoids and changing the activation of cannabinoid receptors (CBRs). Therefore, ECS modulation with new drugs specifically designed for this purpose may be a promising strategy in the treatment of PD. However, fine regulation of the ECS is quite a complex task due to the functional diversity of CBRs in the basal ganglia and other parts of the central nervous system. In this review, the effects of ECS modulators in various experimental models of PD in vivo and in vitro, as well as in patients with PD, are analyzed. Prospects for the development of new cannabinoid drugs for the treatment of motor and non-motor symptoms in PD are presented.
摘要：
脑内源性大麻素系统(ECS)在帕金森病(PD)的分子发病机制中起重要作用。它通过调节内源性大麻素的水平和改变大麻素受体（CBR）的激活而参与该疾病的许多临床表现的形成。因此,使用专门为此目的设计的新药进行ECS调节可能是治疗PD的有希望的策略。然而,由于基底神经节和中枢神经系统其他部分CBR的功能多样性，对ECS的精细调节是一项相当复杂的任务。在这次审查中,ECS调节剂在体内和体外各种PD实验模型中的作用，以及PD患者，被分析。提出了开发用于治疗PD运动和非运动症状的新大麻素药物的前景。
